| 35th week of 2022 patent applcation highlights part 8 |
| Patent application number | Title | Published |
|---|
| 20220273588 | MONOAMINE OXIDASE B INHIBITORS FOR USE IN THE PREVENTION OR TREATMENT OF PROSTATE CARCINOMA - The present invention provides a monoamine oxidase B (MAO-B) inhibitor compound for use in the prevention or treatment of prostate carcinoma (PCa), wherein no selective MAO-A inhibitor compound is co-administered. In the use, other agents for the treatment of PCa is administered and/or radiotherapy is used for the treatment of PCa together with or alternately with the selective compound MAO-B. Another aspect of the invention is the use of a MAO-B inhibitor compound in the manufacture of a medicament for the treatment of PCa. | 2022-09-01 |
| 20220273589 | Diagnosis and Treatment of Vitiligo - Methods of diagnosing and treating vitiligo. | 2022-09-01 |
| 20220273590 | COMPOUNDS FOR PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION - Presented herein, in certain aspects, are methods of preventing, reducing, delaying and treating post-operative cognitive dysfunction, or one or more symptoms thereof, by administering a compound disclosed herein to a subject prior to, during and/or after a medical procedure. | 2022-09-01 |
| 20220273591 | METHODS FOR DETERMINING RISK OF DEVELOPING INSULIN RESISTANCE - Compositions, methods, and kits are provided for determining whether a subject is at risk of developing insulin resistance. In particular, phosphorylated Akt, reactive oxygen species (ROS), SIRT1, eNOS, CDH13, IRS1 and NO production have been identified as biomarkers associated with insulin resistance and type 2 diabetes. The diagnostic methods comprise measuring the level of at least one biomarker in induced pluripotent stem cells derived from somatic cells of the subject, which have been differentiated into endothelial cells (IPSC-ECs). | 2022-09-01 |
| 20220273592 | ANALGESIC FORMULATION FOR PERINEAL PAIN - An analgesic formulation for relief of postpartum perineal pain and discomfort is disclosed. The formulation generally includes an analgesic compound in a solution with herbal ingredients. The formulation has been optimized to provide a stable solution, free from precipitation. A method for treating a perineal area of a woman after giving birth can include: spraying a solution from a pump sprayer onto the perineal area, the solution comprising: a topical anesthetic; and at least one herbal ingredient. | 2022-09-01 |
| 20220273593 | COMPOUNDS AND COMPOSITIONS FOR TREATING KIDNEY DISEASE - The invention is based on a class of dual modulators of soluble epoxide hydrolase (sEH) and farnesoid X receptor (FXR), in particular of compounds having an activity as FXR agonist and sEH inhibitor for the treatment or prevention of kidney diseases and/or fibrotic diseases. The invention provides the compounds for use in such treatments and preventions as well as pharmaceutical compositions comprising the compounds as active ingredients. | 2022-09-01 |
| 20220273594 | Compositions and Use of N-Chlorotaurine for Treatment and Prevention of Respiratory Infections - Composition and methods for treatment or prevention of a respiratory infection in a mammal, including a viral infection, like a coronavirus such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or variants thereof. The compositions and methods include a therapeutically effective amount of about a 1% solution of N-chlorotaurine in water. The methods include administering N-chlorotaurine by nasal spray to the nostrils, by oral spray to the throat, and by nebulizer to the lungs. | 2022-09-01 |
| 20220273595 | COMPOSITIONS AND METHODS FOR TREATING ECZEMA - Disclosed are compositions, methods of treatment using the compositions and methods of preparing the compositions for the treatment of eczema. The compositions may include propionic acid and/or non-steroidal esters of propionic acid. The compositions may further include a corticosteroid, immunomodulator, antibiotic, antibody, colloidal oatmeal, conditioned media prepared by bacterial fermentation, short chain fatty acids, picolinic acid, or emollient. The method of treatment may include analysis of the skin microbiome. | 2022-09-01 |
| 20220273596 | SYNERGISTIC COMBINATION OF S-KETOROLAC AND PREGABALIN IN A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROPATHIC PAIN - The present invention refers to the synergic combination of a non-steroid anti-inflammatory agent such as ketorolac or its S-ketorolac isomer or pharmaceutically acceptable salts thereof and a gamma-aminobutyric (GABA) neurotransmitter analog agent from the group of neuromodulators, such as the active principle pregabalin or pharmaceutically acceptable salts thereof, wherein said combination is useful to be formulated as a pharmaceutical combination to be administered by oral route, indicated for the treatment of neuropathic pain in patients with recurrent neuropathic pain or for post-surgical patients, and as an analgesic and anti-inflammatory therapy. | 2022-09-01 |
| 20220273597 | AGENT FOR PREVENTING, AMELIORATING, OR TREATING PERIODONTAL DISEASE - Provided is a medicine or food useful for preventing, ameliorating or treating periodontal disease. An agent for preventing, ameliorating or treating periodontal disease comprises one or more cysteine derivatives selected from the group consisting of S1PC, SAC and SAMC or a salt thereof as an active ingredient. | 2022-09-01 |
| 20220273598 | METHOD FOR TREATING ALZHEIMER'S DISEASE BY INHIBITING UPTAKE OF AMINO ACIDS BY T CELLS - Provided is the use of a reagent for inhibiting the uptake of amino acids by naive T cells in the preparation of a drug for treating Alzheimer's disease in a subject. | 2022-09-01 |
| 20220273599 | Peripheral Nerve Agonists Suppress Inflammation - Provided herein are methods of treating conditions associated with activation or over-activation of mast cells is acute or chronic urticaria, mastocytosis or any subtype of mastocytosis, pseudo-allergy, any form of dermatitis, such as contact or atopic dermatitis, wound healing, rosacea, acne, or psoriasis, food allergy, or irritable bowel syndrome. The method comprises administering a MRGPRD agonist, such as beta alanine, GABA, β-AIBA, or 5-oxoETE to a patient to treat the condition. Topical, enteric, delayed-release, or aerosol dosage forms comprising beta-alanine also are provided. | 2022-09-01 |
| 20220273600 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF - The present invention relates to a composition comprising a lithium salt of an N-substituted glycine compound and a carrier, wherein the lithium salt of the N-substituted glycine compound is of Formula (I): | 2022-09-01 |
| 20220273601 | COLLAGEN PRODUCTION PROMOTER, WRINKLE IMPROVER, TOPICAL SKIN CARE COMPOSITION, AND BEAUTY FOOD OR BEVERAGE - Provided is a collagen production promoter comprising, as an active ingredient, a triglyceride represented by the following formula (I), wherein R | 2022-09-01 |
| 20220273602 | NUTRITIONAL PRODUCT - The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy. | 2022-09-01 |
| 20220273603 | METHOD FOR TREATING HYPERHIDROSIS - A method for treating hyperhidrosis is disclosed. The method comprises administering a liquid topical preparation to a patient in need thereof. The liquid topical preparation comprises water and oxybutynin or a pharmaceutically acceptable salt thereof. The oxybutynin or pharmaceutically acceptable salt thereof is present in a range of, for example, from 10 mass % to 20 mass % based on a total mass of the liquid topical preparation. | 2022-09-01 |
| 20220273604 | COMPOSITIONS AND METHODS FOR STIMULATING VENTILATORY AND/OR RESPIRATORY DRIVE - A method of attenuating opioid induced ventilatory and/or respiratory depression and/or augmenting opioid induced analgesia in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or an adduct, a pharmaceutically acceptable salt, a tautomer, or a solvate thereof. | 2022-09-01 |
| 20220273605 | COMPOSITIONS AND METHODS FOR TREATMENT OF PRESBYOPIA - The present invention is related to topical ophthalmic compositions comprising one or more active components. The active components in the topical ophthalmic compositions include, but are not limited to carbachol, phospholine iodide and pharmaceutically acceptable salts thereof. Also described herein are methods for the treatment of presbyopia, methods for improving near vision in a subject with presbyopia, and methods for reducing pupil diameter in a subject with presbyopia using the topical ophthalmic compositions. | 2022-09-01 |
| 20220273606 | Polyoxometalate Complexes and Pharmaceutical Compositions - The disclosure relates polyoxometalate complexes and uses in the management, treatment, or prevention of cancer. In certain embodiments, the polyoxometalate complexes comprise polydentate oxygen bridging ligands such as those of the following formula: [POM{(OCH | 2022-09-01 |
| 20220273607 | METHODS OF USING MODIFIED CYTOTOXINS TO TREAT CANCER - The present disclosure provides methods of using prodrugs of small-molecule cytotoxins for the treatment of cancer. In some embodiments, the cancer is a tumor comprising cells that overexpress fatty acid uptake proteins, such as cells that overexpress fatty acid translocase CD36. In some other aspects, the disclosure provides compositions suitable for use in such methods. In some further aspects, the disclosure provides combination therapies that may be suitable used in combination with the use of small-molecule prodrugs disclosed herein. | 2022-09-01 |
| 20220273608 | Methods for Treating Bone-Related Disorders - Provided herein are methods for treating a bone-related disorder in a subject. At least one of a microtubule altering drug, for example, a microtubule disrupting drug or a microtubule stabilizing drug, a TRPV4 agonist or a NOX2 activator is administered to the subject. Also provided are related methods for treating a bone-related disorder in the subject by further administering at least one of an anti-sclerostin agent, a parathyroid hormone agonist, a bisphosphonate, an estrogen mimic, or a selective estrogen receptor modulator with the at least one of a microtubule altering drug, a TRPV4 agonist or a NOX2 activator. | 2022-09-01 |
| 20220273609 | TREATMENT OF VIRAL HEMORRHAGIC FEVERS WITH ETORICOXIB - The subject matter disclosed herein relates to methods of treating viral hemorrhagic fever in a subject in need thereof by administering a pharmaceutically acceptable dose of etoricoxib. In some embodiments, the etoricoxib is administered in combination with other suitable pharmaceutical compositions. | 2022-09-01 |
| 20220273610 | ANTIMYCOTIC - The present invention relates to methods and means for inhibiting or preventing the growth of fungal cells with at least one flavone selected from the group consisting of 5-methoxyflavone, 2′-methoxyflavone, 7-methoxyflavone, 3′,4′,5,7- tetrametoxyflavone, 3′,4′,5′,5,6,7-hexymethoxyflavone, 7,8-benzoflavone and 5,6-benzoflavone for inhibiting or preventing the growth of a fungal cell, wherein said flavone is used in combination with at least one further antimycotic compound selected from the group of azoles, both in an amount to exhibit a synergistic effect compared to the separate use of said flavone and said antimycotic compound. | 2022-09-01 |
| 20220273611 | ORONASAL CBD FORMULATIONS AND USES THEREOF - Provided herein are oronasal formulations including a cannabinoid and N-L-alpha-aspartyl-L-phenylalanine | 2022-09-01 |
| 20220273612 | METHODS AND COMPOSITIONS FOR TREATING CANNABIS USE DISORDER AND MITIGATING CANNABINOID WITHDRAWAL - The present invention provides methods of treating cannabis withdrawal syndrome and other cannabis related conditions, including cannabis use disorder, in a subject, comprising administering to the subject in need thereof an effective amount of a cannabinoid or an effective amount of a cannabinoid and an effective amount of a second active agent, such as gabapentin or a gabapentin analog. | 2022-09-01 |
| 20220273613 | COMPOSITION CONTAINING ARTESUNATE - The present disclosure provides a corn position of artesunate, a process of preparing the same, and a method of treatment. | 2022-09-01 |
| 20220273614 | INTRAVENOUS VITAMIN C THERAPY PROTOCOL FOR THE TREATMENT OF CANCER - Provided herein are methods for treating cancer or chronic illness in a subject including administering an intermittent, high dose of vitamin C and subsequently administering a continuous perfusion of a lower dose of vitamin C. | 2022-09-01 |
| 20220273615 | METHODS OF TREATING POMPE DISEASE - Disclosed herein are novel uses of ADMDP stereoisomers or their derivatives for the manufacture of a medicament for treating Pompe disease. Accordingly, the present disclosure provides a method of treating Pompe disease in a subject. The method includes the step of, administering to the subject a therapeutically effective amount of a compound of formula (I), or a salt, an ester or a solvate thereof, wherein R | 2022-09-01 |
| 20220273616 | COMPOSITIONS AND METHODS FOR INHIBITION OF SARS-COV-2 VIRAL INFECTIONS - The present disclosure provides methods of treating COVID-19 by administering a pharmaceutical composition providing inhibition of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) main protease (M | 2022-09-01 |
| 20220273617 | ANTI-CANCER, ANTI-INFLAMMATORY AND IMMUNOMODULATORY ACTIVITY OF R-CARVEDILOL AND METHODS OF USE - A novel prophylactic therapy for cancer, as well as therapy against DNA damage, inflammation and immunosuppression involves the β-blocker carvedilol, which is a racemic mixture consisting of two enantiomers, S- and R-carvedilol, in 1:1 ratio. S-carvedilol is a β-blocker, with a highly potent antagonizing activity against the β-adrenergic receptors, which is the main mechanism for the drug's pharmacological activity in treatment of high blood pressure and heart failure. Carvedilol—the racemic mixture—prevents ultraviolet radiation induced skin cancer by attenuating DNA damage, reducing inflammation and reversing immunosuppression. The non-β-blocking enantiomer R-carvedilol exhibits the same cancer preventive efficacy as the racemic carvedilol, without disturbing the cardiovascular system. Both carvedilol and R-carvedilol prevent chemical carcinogen-induced lung cancer development and lung inflammation. | 2022-09-01 |
| 20220273618 | PROTEIN HYDROLYSATES - The present invention provides marine protein hydrolysates for use in pharmaceuticals, nutraceuticals functional foods, foods, beverages, and animal feeds, as well as methods for making marine protein hydrolysates. | 2022-09-01 |
| 20220273619 | PHARMACEUTICAL FORMULATIONS COMPRISING SODIUM PALMITOYL-L-PROLYL-L-PROLYLGLYCYL-L-TYROSINATE AND METHODS FOR PREPARING THE SAME - The present invention relates to a pharmaceutical formulation having excellent bioavailability and stability, comprising sodium palmitoyl-L-prolyl-L-prolyl-glycyl-L-tyrosinate (Compound I) as an active ingredient. The pharmaceutical formulation according to the present invention can be usefully used as a dosage form for treating inflammatory bowel disease and the like since Compound I, an active ingredient, is not decomposed in the stomach and released in the intestine. | 2022-09-01 |
| 20220273620 | COMPOSITIONS CONTAINING TOAD SECRETION COMPOUNDS - Disclosed are compositions containing two purified toad secretion tryptamines chosen from the following 5-MeO-DMT, 5-MeO-NMT, 5-Methoxytryptamine, bufobutanoic Acid, bufobutarginine, bufoserotonin A, bufoserotonin B, bufoserotonin C, bufotenidine, bufotenin, bufotenin Oxide, bufotenine-O-Sulphate, bufoviridine, dET, dMT, n-Acetylserotonin, n′-Formylserotonin, n-Methylserotonin, o-Methylbufoviridine, serotonin, tryptamine, and bufopyramide or the salts of these toad secretion tryptamines. The disclosure also relates to formulations, including pharmaceutical formulations, of such a composition and an excipient. Pharmaceutical formulation further containing a therapeutically effective amount of a serotonergic drug, a purified psilocybin derivative, a purified cannabinoid, or a purified terpene a disclosed. Also disclosed are methods of regulating the activity of a neurotransmitter receptor and methods of treating a psychological disorder, a compulsive disorder, or a depressive disorder. | 2022-09-01 |
| 20220273621 | COMPOSITIONS AND METHODS FOR TREATING OCULAR DISORDERS - The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline. | 2022-09-01 |
| 20220273623 | METHODS OF TREATING MULTIPLE SCLEROSIS - The disclosure relates to methods of treating multiple sclerosis. In certain aspects, methods of avoiding worsening of fatigue-related symptoms in a human patient suffering from multiple sclerosis and fatigue, and methods of reducing the number of combined unique active lesions (CUALs) in a patient suffering from multiple sclerosis are disclosed. | 2022-09-01 |
| 20220273624 | NOVEL ANTIVIRAL THERAPIES - The present invention relates to a combination of a picornaviridae capsid binding anti-viral agent and at least one further anti-viral agent for use in a method for treatment of a picornavirales infection in a mammalian subject comprising administering said combination to said mammalian subject. It further relates to an anti-viral agent for use in a method for 5 treatment of a picornavirales infection in a mammalian subject comprising administering said anti-viral agent to said mammalian subject, wherein the picornavirales infection is caused by a virus causing in vivo-expression of a VP1-protein detectable in infected tissue through immunohistochemical staining using an antibody raised against the VP1-protein of Ljungan virus, while said virus is not detectable in said infected tissue using a PCR assay 10 adapted for detection of Ljungan virus, as well as a pharmaceutical composition comprising Ljungan virus VP1 protein and a pharmaceutically acceptable adjuvant. | 2022-09-01 |
| 20220273625 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER - Stress responses involve corticotropin releasing factor (CRF), the two cognate receptors (CRF | 2022-09-01 |
| 20220273626 | THERAPEUTIC USE OF LEVOROTATORY BETA-LACTAMS IN HEMATOPOIESIS, IMMUNO-ONCOLOGY THERAPY, AND REGULATION OF LIPOPROTEIN AND APOLIPOPROTEIN LEVELS - A method for increasing the number of CD4+ T-lymphocytes in the serum of a subject in need of such treatment comprising administering to the subject a pharmaceutical composition comprising an amount of an L-isomer of β-lactam effective to increase the number of CD4+ T-lymphocytes in said patient's serum. | 2022-09-01 |
| 20220273627 | TOPICAL COMPOSITION COMPRISING TACROLIMUS - The present invention relates to a composition for topical application comprising: | 2022-09-01 |
| 20220273628 | EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND OF LSD ANALOGS TO ASSIST PSYCHOTHERAPY FOR GENERALIZED ANXIETY DISORDER OR OTHER ANXIETY NOT RELATED TO LIFE-THREATENING ILLNESS - A method of treating anxiety disorders specifically not associated with causes such as a life-threatening serious somatic illness, by administering a psychedelic to an individual, and treating anxiety and specifically causing reductions in the rating scale score measures of anxiety (STAI global or state or trait anxiety) and/or measures of depression (HDRS or BDI scores) and/or measures of general psychological distress (SCL-90 ratings) in the patient for several weeks beyond administration of the psychedelic. A method of treating anxiety, by administering a psychedelic (preferably LSD) to an individual having anxiety not associated with causes such as a life-threatening serious somatic illness, and inducing positive acute drug effects and positive long-term therapeutic effects in the individual. | 2022-09-01 |
| 20220273629 | METHODS OF TREATING DISORDERS ASSOCIATED WITH ELEVATED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR - Methods of treating a disorder associated with elevated NMDAR antibodies in a patient in need thereof are provided comprising, for example, administering to the patient an effective amount of a spiro-β-lactam compound. | 2022-09-01 |
| 20220273630 | TRIPLE COMBINATION FORMULATIONS FOR ANTIEMETIC THERAPY - The disclosure relates to chemotherapy treatments and in particular, formulations for antiemetic therapy. Parenteral formulations comprising Palonosetron, NK | 2022-09-01 |
| 20220273632 | TREATMENT FOR PARKINSON'S DISEASE - The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I | 2022-09-01 |
| 20220273633 | SUSTAINED RELEASE DRUG DELIVERY SYSTEMS AND RELATED METHODS - The present disclosure provides for methods of producing analgesia in a subject. In some cases, methods produce analgesia in a subject undergoing arthroscopic subacromial decompression surgery. The present disclosure also relates to improved sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises bupivacaine N-oxide at a level less than 1 wt %, based on weight of the composition. In some cases, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided. | 2022-09-01 |
| 20220273634 | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) - The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent β-thalassemia. | 2022-09-01 |
| 20220273635 | SOLUTION FORMULATIONS OF CX-011 - Provided herein are solution formulations of CX-011 and related methods for making solution formulations of CX-011. Also provided are methods of treating an inflammatory disorder, such as osteoarthritis, or cancer in a subject in need thereof by administering an effective amount of the solution formulations of CX-011. | 2022-09-01 |
| 20220273636 | Novel compounds for use in treating depression and migraine - The invention relates to amide-derivatives of 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid for use in a treatment for preventing or suppressing symptoms associated with mood disorders, headaches and migraine. The compounds of the invention can be used to treat any subject suffering from a mood disorder, headaches and/or migraine but can specifically be used to treat a mood disorder, headaches and/or migraine in patients suffering from a mitochondrial disease. | 2022-09-01 |
| 20220273637 | NOVEL PFAR-INHIBITING COMPOUNDS - The invention relates to novel compounds which are inhibitors of the ribosome protein chaperone activity (“protein folding activity of the ribosome” or “PFAR”). More particularly, the invention relates to their use as PFAR-inhibitors, to compositions comprising them and to methods for treating proteinopathies. | 2022-09-01 |
| 20220273638 | DESLORATADINE AND/OR LORATADINE FOR TREATMENT AND/OR PROPHYLACTIC TREATMENT OF MELANOMA - Disclosed herein is a pharmaceutical composition comprising a H1 antihistamine being desloratadine and/or loratadine, for use in the treatment and/or prophylactic treatment of melanoma. | 2022-09-01 |
| 20220273639 | PROCESSES FOR PREPARING ARIMOCLOMOL CITRATE AND INTERMEDIATES THEREOF - The present disclosure relates to a process for preparing arimoclomol, arimoclomol citrate and key intermediates, such as ORZY-01, thereof. The disclosure further relates to a process for preparing high purity arimoclomol citrate and methods of using the same. | 2022-09-01 |
| 20220273640 | USE OF KOUMINE IN PREPARATION OF MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE - The present invention relates to novel use of koumine, an alkaloid monomer from | 2022-09-01 |
| 20220273641 | Method for treating coronavirus infections including SARS-CoV-2 - The disclosure is directed to methods of using Floctafenine, or pharmaceutically acceptable salt of thereof, or derivative thereof, for treatment of patients with coronavirus infection including SARS-CoV-2. This compound is capable of inhibiting SARS-CoV-2 Main protease with highest specificity that allows the highest precision binding to the active site of SARS-CoV-2 Main protease. As a result of this targeted inhibition viral replication is expected to be blocked. That is expected to be a successful treatment of coronavirus infection including SARS-CoV-2. In addition to capability of inhibiting viral replication, Floctafenine is known for its anti inflammatory properties. That is expected to contribute to improving the outcome of subjects with inflammatory response as a result of coronavirus infection including SARS-CoV-2. Drug Repurposing is also expected to reduce healthcare costs given how laborious de novo drug discovery projects have been. | 2022-09-01 |
| 20220273642 | COMPOSITION FOR INHIBITING CANCER METASTASIS AND TREATING CANCER - The present disclosure relates to an effect of inhibiting cancer metastasis by treatment of chlorphenesin and hydroxychloroquine alone or in combination. Chlorphenesin or hydroxychloroquine has the effect of inhibiting the metastasis and invasion of cancer cells. In particular, since it was identified that a combination thereof has a synergistic action, it is possible to effectively prevent or treat cancer metastasis by administering chlorphenesin and hydroxychloroquine respectively or in combination thereof. | 2022-09-01 |
| 20220273643 | METHOD OF TREATING KRAS-ASSOCIATED CANCERS - Disclosed are methods of treating cancer characterized by expression of at least one KRAS mutation, using a compound of Formula I, below, or a pharmaceutically acceptable salt thereof, or a prodrug thereof: (I) Also disclosed are methods of altering the level of KRAS or cMet in a cell characterized by expression of at least a KRAS mutation with the compound of Formula I. | 2022-09-01 |
| 20220273644 | Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders - The present invention relates to compounds, i.e. ergoline derivatives, such as lysergic acid diethylamide, or pharmaceutically acceptable salts thereof for use in a method of treating (alleviating), preventing, reducing the symptoms of and/or slowing down the progression of a neurological and/or psychiatric disorder, such as mild cognitive impairment or Alzheimer's disease. In some aspects, the present invention relates to a method of treating, preventing, reducing the symptoms of and/or slowing down the progression of a neurological and/psychiatric disorder, which uses an ergoline derivative such as lysergic acid diethylamide or a pharmaceutically acceptable salt thereof. | 2022-09-01 |
| 20220273645 | NALTREXONE FORMULATION - A lactose free, stable pharmaceutical composition having naltrexone or its pharmaceutically acceptable salt thereof. Also disclosed is a process for the preparation of the composition and its use in a method for the treatment of Crohn's disease. | 2022-09-01 |
| 20220273646 | PHARMACEUTICAL COMPOSITION OF TEMOZOLOMIDE - A stable pharmaceutical composition of temozolomide for oral administration. The pharmaceutical composition is in the form of powder for oral suspension, wherein the said powder is reconstituted with a liquid vehicle just before administration. Further the invention relates to process for the preparation of said pharmaceutical composition and its packaging in individual doses. | 2022-09-01 |
| 20220273647 | ORAL PHARMACEUTICAL COMPOSITION CONTAINING HETEROCYCLIC COMPOUND - Provided is a means that is capable of preventing initial excessive release of an active ingredient and that allows for sustained release of the active ingredient in a pharmaceutically active amount over a long period of time. | 2022-09-01 |
| 20220273648 | METHOD FOR TREATING CANCER USING A BCL-2 INHIBITOR IN CONJUNCTION WITH AN ALPHA-EMITTING RADIOIMMUNOTHERAPEUTIC - This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets the cancer cell, wherein the amounts of BCL-2 inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death. | 2022-09-01 |
| 20220273649 | 5-HETEROARYL-1H-PYRAZOL-3-AMINE DERIVATIVE - The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1: | 2022-09-01 |
| 20220273650 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS - Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma. | 2022-09-01 |
| 20220273651 | METHODS OF TREATING CROHN'S DISEASE AND ULCERATIVE COLITIS - The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor. | 2022-09-01 |
| 20220273652 | PHARMACEUTICAL COMPOSITION COMPRISING HMG-COA REDUCTASE INHIBITORS AND FENOFIBRATE - A multilayer, pharmaceutical composition having a fixed dose combination of rosuvastatin or a pharmaceutically acceptable salt thereof and fenofibrate or a pharmaceutically acceptable salt thereof, wherein the fenofibrate or the pharmaceutically acceptable salt thereof and the rosuvastatin or the pharmaceutically acceptable salt thereof are present in separate layers, namely a fenofibrate layer and a rosuvastatin layer, wherein fenofibrate and rosuvastatin are immediately released from the fenofibrate layer and the rosuvastatin layer, respectively, and wherein the fenofibrate layer having micronized fenofibrate. A process for the preparation of the composition is also disclosed. | 2022-09-01 |
| 20220273653 | Aqueous Suspensions of TMC278 - This invention concerns pharmaceutical compositions for administration via intramuscular or subcutaneous injection, comprising micro- or nanoparticles of the NNRTI compound TMC278, suspended in an aqueous pharmaceutically acceptable carrier, and the use of such pharmaceutical compositions in the treatment and prophylaxis of HIV infection. | 2022-09-01 |
| 20220273654 | METHODS OF TREATING CANCER BY TARGETING COLD TUMORS - Methods are provided for the treatment of cancer or neoplastic diseases and the like, by administering 4-[2-(4-amino-piperidin-1-yl)-5-(3-fluoro-4-methoxy-phenyl)-1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl]-2-fluoro- benzonitrile (compound of Formula (I)) or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1) to patients in need thereof. Methods are further drawn to administering compositions described herein to patients having neoplastic cells that express RCOR2. | 2022-09-01 |
| 20220273655 | PRODUCING ASTROCYTES USING SMALL MOLECULES - Disclosed herein are methods of reprograming autologous tissues or cells into astrocytes or astroglial progenitor cells using one or more small molecule compounds only without any transgenes. Also disclosed are methods of preventing or treating neurodegenerative diseases or neurological disorders associated with dysfunction of astrocytes, such as Alzheimer's Disease, by transplanting the astrocytes or astroglial progenitor cells produced by the methods disclosed herein into the brain of a subject suffering from the neurodegenerative disease or neurological disorder. | 2022-09-01 |
| 20220273656 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF - Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or | 2022-09-01 |
| 20220273657 | AMORPHOUS SOLID DISPERSIONS OF DASATINIB AND USES THEREOF - Amorphous solid dispersions and pharmaceutical compositions of the protein kinase inhibitor dasatinib. The pharmaceutical compositions may be used in methods of treating a proliferative disorder such as cancer, or in methods of delivering dasatinib to patients without regard to whether the patient is concurrently administered a gastric acid-reducing agent, or without regard to whether the patient has an elevated gastric pH. The compositions may be particularly suitable for patients afflicted by achlorhydria or hypochlorhydria, or | 2022-09-01 |
| 20220273658 | SMALL MOLECULE LIVER X RECEPTOR MODULATORS AND USES THEREOF - Small molecule liver X receptor (LXR) modulators, and derivatives thereof, exhibit activity against tumor cells and less or no activity against dividing non-malignant cells, target the liver X receptor and disrupt key metabolic pathways preferred by cancer cells, and activate a newly discovered cell death mechanism which is distinct from the cell death induced by chemotherapeutic agents. These compounds can thus be a less toxic alternative to chemotherapy and can be used in combination with chemotherapy to increase efficacy and decrease the likelihood of cancer cells developing resistance. Moreover, they can be used as second-line treatments when chemotherapies are ineffective or if cancer cells develop resistance over time. | 2022-09-01 |
| 20220273659 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS - Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology. | 2022-09-01 |
| 20220273660 | MEK INHIBITOR FOR TREATMENT OF STROKE - The present invention relates to a MEK inhibitor and compositions thereof, for use in the treatment of stroke, in particular treatment of subarachnoid haemorrhage (SAH) | 2022-09-01 |
| 20220273661 | USE OF SEPIAPTERIN AND METABOLITES THEREOF TO TREAT RADIATION EXPOSURE - The invention provides methods for treating radiation exposure in a subject by administering sepiapterin, tetrahydrobiopterin, or dihydrobiopterin. | 2022-09-01 |
| 20220273662 | USE OF SILDENAFIL AND ROCK INHIBITORS FOR TREATING STROKE OR SEQUELAE FOLLOWING STROKE - The present invention relates to a use of a pharmaceutical composition for treating stroke or sequelae following stroke, the composition comprising a phosphodiesterase type 5 activity inhibitor and a Rho-associated kinase (ROCK) inhibitor. | 2022-09-01 |
| 20220273663 | FORMULATIONS OF AN AXL/MER INHIBITOR - The present application relates to pharmaceutical formulations and dosage forms of an AXL/MER inhibitor, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, including methods of preparation thereof, which are useful in the treatment of AXL/MER mediated diseases such as cancer. | 2022-09-01 |
| 20220273664 | Mitochondrial Targeted Releasable Linker - There is described herein compound comprising a mitochondrial targeting portion, a cargo portion including a drug unit, and a linker conjugating the mitochondrial targeting portion and the cargo portion, the linker portion cleavable in a mitochondrion of a cell for preferentially releasing the cargo portion within the mitochondrion as compared to a cytoplasm of the cell. | 2022-09-01 |
| 20220273665 | METHODS OF TREATING INFLAMMATORY BOWEL DISEASES THAT TARGET RIPK2 - Described herein are methods, systems, compositions, and kits useful for the diagnosis and/or treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis in a subject, with an antagonist of RIPK2 activity or expression. The present disclosure relates to methods and systems for identifying and stratifying patients suitable for treatment with the antagonist to RIPK2 activity or expression, as described herein. | 2022-09-01 |
| 20220273666 | NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR - Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein. | 2022-09-01 |
| 20220273667 | PI3K INHIBITOR FOR USE IN THE THERAPY OF B CELL LYMPHOMA - The present invention relates to a compound of formula (I), or its pharmaceutically acceptable salt. The compound, or its pharmaceutically acceptable salt, is useful as a PI3K inhibitor and therefore in therapy. In particular, the compound, or its pharmaceutically acceptable salt, has utility in the treatment of B cell lymphoma. | 2022-09-01 |
| 20220273668 | IRAK4 DEGRADERS AND USES THEREOF - The present invention provides IRAK4 degraders, formulations and unit dosage forms thereof, and methods of use thereof. | 2022-09-01 |
| 20220273669 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES - The present invention relates to Compounds of Formula I: I and pharmaceutically acceptable salts or prodrug thereof. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treatment of cardiometabolic diseases including high blood pressure, heart failure, kidney disease, and diabetes in a subject. | 2022-09-01 |
| 20220273670 | MODIFIED RELEASE SUSPENSION OF ESLICARBAZEPINE - The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes. | 2022-09-01 |
| 20220273671 | TOPICAL FORMULATIONS FOR TREATMENT OF PERIPHERAL NEUROPATHIES - Aspects relate to topical formulations of a muscarinic acetylcholine receptor antagonist or a salt or derivative in combination with DMSO and a polyalkylene glycol alkyl ether. The topical formulations may include pirenzepine as the muscarinic acetylcholine receptor antagonist. In addition, the polyalkylene glycol alkyl ether may be a polyethylene glycol alkyl ether. | 2022-09-01 |
| 20220273672 | ORALLY INHALED AND NASAL BENZODIAZEPINES - The present invention relates to Orally Inhaled and Nasal Drug Product (OINDP) comprising a benzodiazepine, in particular remimazolam. | 2022-09-01 |
| 20220273673 | BONE-BINDING COMPOUNDS - Disclosed herein are compounds having the following Formula (I) or a pharmaceutically acceptable salt form thereof: B-L-C (I) wherein B is a bone-binding moiety; L is a linker; and C is a cationic steroid antimicrobial (CSA) moiety, pharmaceutical compositions comprising the compounds, and methods of using the compounds or pharmaceutical compositions for the treatment of an infection or osteomyelitis in a bone of a subject, promotion of bone formation in a subject, or treatment of bone cancer or metastatic bone cancer in a subject. | 2022-09-01 |
| 20220273674 | EXTENDED-RELEASE DRUG DELIVERY COMPOSITIONS - An extended-release drug delivery composition and method of administering the same is provided. The composition comprises microspheres loaded with a biologically-active agent and suspended in a soluble polymer capable of forming a film upon injection onto a biological surface. | 2022-09-01 |
| 20220273675 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF - Provided are a novel bile acid derivative for treating fatty liver disease, a pharmaceutical composition thereof, and a use in the preparation of a medicine for treating and improving diseases and symptoms mediated or caused by FXR or TGR5. The bile acid derivative of the present invention inhibits or delays the metabolism of bile acid by bacterial BSH/7α dehydroxylase in the intestine and greatly prolongs the effective survival time of bile acid in the intestine. The bile acid derivative and the pharmaceutical composition thereof can significantly stimulate bile acid membrane receptor TGR5, promote the secretion of glucagon-like peptide 1 from enteroendocrine cells, reduce liver fat accumulation, significantly improve liver function and increase glucose tolerance, thereby having an excellent effect on the treatment of fatty liver disease. | 2022-09-01 |
| 20220273676 | CHOLECALCIFEROL FOR USE IN THE TREATMENT OF CELIAC DISEASE - The use of cholecalciferol is described as an active agent in the treatment of celiac disease, in the reduction of intestinal villous atrophy, and in the protection and regeneration of the intestinal epithelium. Also described are pharmaceutical compositions or food supplements, as well as foods for celiacs, including cholecalciferol and suitable excipients for use in the treatment of celiac disease, in the reduction of intestinal villous atrophy and in the protection and regeneration of the intestinal epithelium. | 2022-09-01 |
| 20220273677 | DENDRIMER FORMULATIONS - Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer. | 2022-09-01 |
| 20220273678 | Compositions and Methods for Inhibiting and Treating Coronavirus Infections - Disclosed herein are methods of using one or more triphenylphosphonium compounds, to prevent, inhibit, and/or treat infections and symptoms caused by infection by a coronavirus, such as SARS-CoV-2. | 2022-09-01 |
| 20220273679 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DAMAGE TO SKIN - A method and/or composition for treating or suppressing ultraviolet radiation sensitivity in a subject in need thereof. The method involves in one embodiment, administering a therapeutically effective amount of an agent which activates or increases the expression or activity of ADAM 17, or activates or increase the release of EGFR ligands, or increases epidermal EGFR in the subject's Langerhans cells. Compositions can include topical ointments, sunscreens, creams and sprays for topical application to the skin. These methods and compositions are useful particularly for patients with systemic lupus erythematosus, among other inflammatory skin conditions. | 2022-09-01 |
| 20220273680 | Methods of Treating Psychological and Brain Disorders - Provided herein are methods for preventing or treating a psychological disorder. A serotonin agonist or an agonist of serotonin receptors is administered separately, sequentially or simultaneously in combination with a serotonin receptor 2A antagonist. | 2022-09-01 |
| 20220273681 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING RESPIRATORY RELATED DISEASES AND CONDITIONS WITH XYLITOL-HEADGROUP LIPID ANALOGS - The invention generally relates to methods to prevent and/or inhibit viral infection as well as to inhibit inflammation and/or pathogen infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. The invention also relates to methods to prevent or inhibit respiratory syncytial virus (RSV) infection by administering at least one xylitol lipid analog or compositions comprising at least one xylitol lipid analog to an individual. | 2022-09-01 |
| 20220273682 | ACEFAPC FOR THE TREATMENT OF ACETYLCHOLINE-DEPENDENT DISEASES - The present invention relates to AceFaPC (1-Acetyl-2-Fatty acyl-glyceroPhosphoCholine) for use in the prevention and treatment of diseases associated with an acetylcholine deficiency. The invention also relates to the AceFaPC molecule in which Fa represents an unsaturated acyl comprising at least 14 carbon atoms, and the pharmaceutical compositions comprising same. | 2022-09-01 |
| 20220273683 | BORON-CONTAINING SMALL MOLECULES - Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed. | 2022-09-01 |
| 20220273684 | Systems and Methods to Identify Pancreatic Ductal Adenocarcinoma and Uses Thereof - Embodiments herein describe systems and methods to identify and treat pancreatic ductal adenocarcinoma (PDAC) based on cell of origin. Various embodiments comprise assessing transcriptomic data to identify gene expression profiles for the cancer. Based on type of cancer, additional embodiments treat individuals for PDAC. Further embodiments identify possible treatments for a PDAC tumor, by screening effective treatments, including drugs. | 2022-09-01 |
| 20220273685 | PULSATILLA CHINENSIS EXTRACT IN PREPARING DRUG FOR TREATING VIRAL AND/OR BACTERIAL DISEASES - Use of the compound | 2022-09-01 |
| 20220273686 | PHARMACEUTICAL COMPOSITION FOR PRODUCING SAFE AMOUNT OF NITRIC OXIDE AND USE THEREOF - A pharmaceutical composition for producing a safe amount of nitric oxide (NO) in vivo and use thereof. The pharmaceutical composition comprises the following components: an NO toxicity decreasing agent, an optional NO extender, and a nitric oxide synthase inducer. Provided is the pharmaceutical composition which has high versatility and extremely effectively treats pathogenic microorganism infections. A new medicinal activity of 5-methyltetrahydrofolic acid, NMN, and dehydroascorbic acid is found, which has a variety of active effects on an immune system caused by pathogen infection, and capable of being used for treating or preventing disease caused by virus infections and other pathogen infections. | 2022-09-01 |
| 20220273687 | ANTI-TUMOR EFFECTIVE COMPONENT OF HEDYOTIS DIFFUSA, PREPARATION METHOD THEREFOR AND USE THEREOF - The present invention relates to the field of medicines, in particular to an anti-tumor effective component of | 2022-09-01 |
| 20220273688 | Treatment of Glycosylation Deficiency Diseases - Uridine triacetate or other uridine prodrugs are used to treat genetic glycosylation disorders by administering them in an amount sufficient to raise plasma uridine in the patient to a level greater than 30 micromolar. They can be administered alone or in combination with a sugar whose transfer is defective in the glycosylation disorder being treated. | 2022-09-01 |
| 20220273689 | POTENTIATION OF ANTIVIRAL NUCLEOBASES AS RNA VIRUS THERAPY - Described herein are methods of treating RNA virus infections with a therapeutic combination of an antiviral nucleobase compound and a de novo nucleotide biosynthesis inhibitor (DNNBi). An aspect of the invention is a method for the treatment of an RNA virus infection comprising administering a therapeutic combination as a combined formulation or by alternation to a patient, wherein the therapeutic combination comprises therapeutically effective amounts of (i) an antiviral nucleobase or a pharmaceutically acceptable salt thereof, and (ii) a de novo nucleotide biosynthesis inhibitor (DNNBi) or a pharmaceutically acceptable salt thereof. | 2022-09-01 |
